Holding(s) in Company
21 August 2026
Physiomics plc
("Physiomics" or the "Company")
Holding in Company
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that it was notified on 20 August 2026 by Robert McFadden that as of 18 August 2026 he holds 13,678,940 ordinary shares of 0.4 pence each in the Company representing 3.02% of the Company's issued share capital, following a market purchase at 0.47 pence per share. The interest is held directly.
ENDS
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Mike Whitlow
Email: info@physiomics.co.uk
Strand Hanson Ltd (NOMAD and Broker)
James Dance & James Bellman
Tel: +44 (0) 20 7409 3494
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDHOLEFLFLQVLBBBK
